These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 35047549)

  • 21. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
    Ruetsch O; Viala A; Bardou H; Martin P; Vacheron MN
    Encephale; 2005; 31(4 Pt 1):507-16. PubMed ID: 16389718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D
    Sykes DA; Moore H; Stott L; Holliday N; Javitch JA; Lane JR; Charlton SJ
    Nat Commun; 2017 Oct; 8(1):763. PubMed ID: 28970469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management.
    Baptista T; De Mendoza S; Beaulieu S; Bermúdez A; Martinez M
    Metab Syndr Relat Disord; 2004; 2(4):290-307. PubMed ID: 18370698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Neuropsychopharmacology; 2004 Dec; 29(12):2200-7. PubMed ID: 15328528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine.
    Weiner I; Schiller D; Gaisler-Salomon I; Green A; Joel D
    Behav Pharmacol; 2003 May; 14(3):215-22. PubMed ID: 12799523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
    Weiner I
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):257-97. PubMed ID: 12601500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antipsychotics].
    Cattapan-Ludewig K; Seifritz E
    Ther Umsch; 2009 Jun; 66(6):402-6. PubMed ID: 19496035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic Treatment Associated With Increased Mortality Risk in Patients With Dementia. A Registry-Based Observational Cohort Study.
    Schwertner E; Secnik J; Garcia-Ptacek S; Johansson B; Nagga K; Eriksdotter M; Winblad B; Religa D
    J Am Med Dir Assoc; 2019 Mar; 20(3):323-329.e2. PubMed ID: 30824220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EPS profiles: the atypical antipsychotics are not all the same.
    Weiden PJ
    J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of long-term clozapine administration. Frequency of cardiomyopathy and hyponatraemia: two cross-sectional, naturalistic studies.
    Serrano A; Rangel N; Carrizo E; Uzcátegui E; Sandia I; Zabala A; Fernández E; Tálamo E; Servigna M; Prieto D; Connell L; Baptista T
    Aust N Z J Psychiatry; 2014 Feb; 48(2):183-92. PubMed ID: 23985160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.
    Jafari S; Fernandez-Enright F; Huang XF
    J Neurochem; 2012 Feb; 120(3):371-84. PubMed ID: 22103329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.
    Arnt J; Skarsfeldt T
    Neuropsychopharmacology; 1998 Feb; 18(2):63-101. PubMed ID: 9430133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-generation antipsychotics and extrapyramidal adverse effects.
    Divac N; Prostran M; Jakovcevski I; Cerovac N
    Biomed Res Int; 2014; 2014():656370. PubMed ID: 24995318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.
    Choi KH; Higgs BW; Weis S; Song J; Llenos IC; Dulay JR; Yolken RH; Webster MJ
    BMC Psychiatry; 2009 Sep; 9():57. PubMed ID: 19758435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era.
    Basu A; Meltzer HY
    Schizophr Res; 2006 Sep; 86(1-3):99-109. PubMed ID: 16753284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2003; (1):CD001359. PubMed ID: 12535408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.